The excerpt is incomplete and does not provide sufficient details to determine the nature of the event.

Results of Operations and Financial Condition On August 6, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Entry into a Material Definitive Agreement. On June 11, 2026, Apyx Medical Corporation (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Stavros Vizirgianakis, the Chairman of the Company’s Board of Directors (the “Board”), in connection with Mr. Vizirgianakis’ appointment as Executive Chairman of the Board. Pursuant to the Letter Agreement and his appointment as Executive Chairman, Mr. Vizirgianakis will provide strategic leadership and governance oversight, assis…

Results of Operations and Financial Condition On May 7, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the first quarter ended March 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On March 10, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the fourth quarter and year ended December 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On January 12, 2026, Apyx Medical Corporation (the “Company”) issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to

Entry into a Material Definitive Agreement. On November 18, 2025, Apyx Medical Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”) pursuant to which the Company will issue and sell to the Underwriter pursuant to the Underwriting Agreement 2,762,431 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) at an offering price of $3.62 and grant to the Underwriter an o…

Results of Operations and Financial Condition On November 6, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the third quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On August 7, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On May 8, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the first quarter ended March 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On March 13, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the fourth quarter and year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Chief Operating Officer — Shawn Roman: The company hired Shawn Roman as its Chief Operating Officer with a comprehensive employment agreement.

Results of Operations and Financial Condition On January 13, 2025, Apyx Medical Corporation (the “Company”) issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to

Results of Operations and Financial Condition On November 8, 2024, the Company issued a press release reporting on its results of operations for the third quarter ended September 30, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. Amendment to the Credit and Guaranty Agreement On November 7, 2024, Apyx Medical Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Credit Agreement and Guaranty (the “Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (“Perceptive”) (as initial lender and a…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Executive Vice President of Sales and Marketing — Todd Hornsby: The company terminated Todd Hornsby without cause.

Results of Operations and Financial Condition On August 8, 2024, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On May 9, 2024, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the first quarter ended March 31, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Chairman of the Board and Director — Andrew Makrides: Andrew Makrides retired as a director and Chairman of the Board, succeeded by Stavros G. Vizirgianakis.

Entry into a Material Definitive Agreement On May 7, 2024, Apyx Medical Corporation (the “Company”) entered into a letter agreement (the “Agreement”) with Stavros G. Vizirgianakis. Pursuant to the Agreement, the Company’s board of directors (the “Board”) accepted the resignation of Andrew Makrides as a director and Chairman of the Board and the Board appointed Mr. Vizirgianakis to serve as a director and Chairman of the Board to fill the vacancy created by Mr. Makrides’ retirement. Pursuant t…

Results of Operations and Financial Condition On March 21, 2024, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the fourth quarter and year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under

Results of Operations and Financial Condition On January 8, 2024, Apyx Medical Corporation (the "Company") issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to

Chief Financial Officer — Matthew Hill: Appointment of Matthew Hill as Chief Financial Officer.